How UCLA Health’s Legacy of Theranostics Innovation Transforms Cancer Care
UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...
Which Foods Contain Red Dye 3? What To Be Aware Of After FDA Ban, Per Food Safety Expert
Just a few weeks ago on January 15, the Food and Drug Administration (FDA) under the Biden administration revoked authorization of the additive red dye 3, meaning it will be banned from foods and ...
phillyvoice.com2d
A new blood test accurately screens for colorectal cancer, researchers say
Research that has not yet been peer-reviewed shows the newest blood test is more than 80% accurate in detecting colon cancer ...
STAT11d
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
A grim prognosis, a gamble and one patient’s fight to defy cancer
After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...
As Trump and RFK Jr. move to upend drug making, Seattle biotech bets on science
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
Boise State Public Radio1d
The link between artificial food dyes and ADHD in kids
Studies going back decades have shown a potential link between artificial food dyes and attention deficit hyperactivity ...
Cure Today2d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
Cure Today7h
Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.